Status:
COMPLETED
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
Lead Sponsor:
University of Michigan
Conditions:
Covid19
Kidney Diseases
Eligibility:
All Genders
18+ years
Brief Summary
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult...
Detailed Description
The Michigan Medicine COVID-19 Cohort is a prospective observational cohort study of patients hospitalized specifically for COVID-19 at the University of Michigan Health System in Ann Arbor. Medical r...
Eligibility Criteria
Inclusion
- Confirmed SARS-CoV-2 infection
- Hospitalized primarily for the treatment of COVID-19
Exclusion
- SARS-CoV-2 positive but hospitalized for non-COVID-19 reasons
Key Trial Info
Start Date :
March 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
3402 Patients enrolled
Trial Details
Trial ID
NCT04706533
Start Date
March 23 2020
End Date
December 1 2022
Last Update
October 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109